NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT05932212 2025-03-12AK104 for Recurrent or Metastatic Vulvar CancerAkesoPhase 2 Recruiting20 enrolled
NCT05694728 2023-01-23A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV VaccineBeijing Health Guard Biotechnology, IncPhase 2 Completed780 enrolled
NCT00520598 2015-11-26Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)Merck Sharp & Dohme LLCPhase 2 Completed511 enrolled
NCT00551187 2015-06-08A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)Merck Sharp & Dohme LLCPhase 2 Completed620 enrolled